View Post

Evaluating Use of Bone-Modifying Agents to Treat Skeletal-Related Events in Cancer

In In The News by Barbara Jacoby

By: Laura Joszt From: ajmc.com Skeletal-related events are frequent complications in patients with cancers. Two abstracts analyzed the use of bone-modifying agents in patients with newly diagnosed multiple myeloma and breast cancer. Skeletal-related events are frequent complications in patients with cancers. Two abstracts presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting analyzed the use of bone-modifying …

View Post

Oak Park Woman Benefits from Clinical Trial for Multiple Myeloma

In Clinical Trials by Barbara Jacoby

By: Elizabeth Katz From: thejewishnews.com Barbara Robins, 75, of Franklin has lived a full life, working as a financial adviser while also keeping herself in optimum health and enjoying her friends, travel and art. Because she’s kept herself so healthy and active, a diagnosis of multiple myeloma in 2015 stopped her in her tracks. “It was completely a surprise,” she …

View Post

Approval decision delay seen as positive for Karyopharm

In Clinical Trials by Barbara Jacoby

By: Andrew Dunn From: biopharmadive.com Dive Brief: The Food and Drug Administration pushed back the deadline for an approval decision by three months for Karyopharm Therapeutics’ experimental cancer drug — and investors celebrated the delay. The drugmaker gave the agency additional clinical information on selinexor’s accelerated approval application as a late-line treatment for relapsed refractory multiple myeloma, leading the FDA …

View Post

STEM CELL TRANSPLANTS EXTEND LIFE FOR MULTIPLE MYELOMA PATIENTS

In In The News by Barbara Jacoby

Researchers at UC Davis have confirmed that autologous hematopoietic stem cell transplant improves survival for people suffering from multiple myeloma, yet many potentially eligible patients never undergo the procedure. Using data from two extensive California databases, the team showed median overall survival for transplant patients was around 73 months, while controls who did not receive the procedure lived around 50 …

View Post

Fox Chase Enrolling Patients in ONC201 Multiple Myeloma Trial

In In The News by Barbara Jacoby

Oncoceutics, Inc. announced that the first patient has begun treatment in a clinical trial of the company’s lead compound, ONC201, at the Fox Chase Cancer Center (FCCC) in relapsed/refractory multiple myeloma. The Phase I/II trial, identified as NCT02863991 on www.clinicaltrials.gov, will investigate the use of ONC201 in combination with dexamethasone in adult patients with multiple myeloma who have relapsed or …

View Post

Scientists To Trial Personalized Vaccine Against One Type Of Cancer

In In The News by Barbara Jacoby

By: Alfredo Carpineti From: iflscience.com Researchers are starting a ground-breaking clinical trial that will use a patient’s own tumor and immune cells to fight the reoccurrence of a type of blood cancer known as multiple myeloma. The trial will be led by the University of Wisconsin Carbone Cancer Center and conducted by 14 other different cancer research centers. It will …

View Post

Israeli Company’s Vaccine Blocks 90% of Cancer Types

In In The News by Barbara Jacoby

By Arutz Sheva Staff From: israelnationalnews.com Vaxil BioTherapeutics’s ImMucin trains immune system to fight cancer cells and prevent the disease’s return for early stages and remission. An Israeli biotech company is developing a vaccine for cancer that it says can help prevent the return of the lethal disease for 90% of the different types of cancer. Vaxil BioTherapeutics based in …

What’s attracting big pharma to pre-clinical deals?

In In The News by Barbara Jacoby

by Stephanie Baum Roche’s move to skip over Inovio’s (NYSE: INO) late stage drugs for cervical cancer and Hepatitis C and make a beeline for its preclinical DNA vaccines for prostate cancer and Hep B was initially a little puzzling. Investors have preferred to park their money further upstream when products are in the clinic and they’ve been derisked. Big …